Statement Of Cash Flows [Abstract]

Pharming Group N.V. - Filing #1883078

Concept 2022-01-01 to
2022-12-31
2021-01-01 to
2021-12-31
Statement of cash flows [abstract]
Cash flows from (used in) operating activities [abstract]
Adjustments for finance income
4,485,000 USD
14,906,000 USD
Cash flows from (used in) operations before changes in working capital
23,995,000 USD
42,750,000 USD
Increase (decrease) in working capital
387,000 USD
4,961,000 USD
Adjustments for decrease (increase) in trade and other receivables
2,364,000 USD
5,918,000 USD
Adjustments for increase (decrease) in trade and other payables
11,992,000 USD
5,193,000 USD
Adjustments for depreciation and amortisation expense and impairment loss (reversal of impairment loss) recognised in profit or loss
13,188,000 USD
19,610,000 USD
Adjustments for gain (loss) on disposal of investments in subsidiaries, joint ventures and associates
12,242,000 USD
USD
Cash flows from (used in) investing activities [abstract]
Cash flows from (used in) decrease (increase) in restricted cash and cash equivalents
273,000 USD
467,000 USD
Proceeds from sales of interests in associates
7,300,000 USD
USD
Payments for development project expenditure
USD
2,530,000 USD

Talk to a Data Expert

Have a question? We'll get back to you promptly.